Teleflex Incorporated

What they do

Teleflex designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers in critical care and surgical applications. It sells worldwide through a direct sales force and distributors, with major manufacturing in the Czech Republic, Malaysia, Mexico and the U.S. Products are primarily Class I and Class II devices, most requiring 510(k) FDA clearance rather than the PMA process. Following 2021-2023 respiratory divestitures and the pending Strategic Divestitures, the company is narrowing its focus to remaining core businesses.

Revenue drivers

• Vascular business — Cited by management as a leader of second quarter 2026 performance; the company is integrating the acquired Biotronik Vascular Intervention business, whose integration delay drove the reduced revenue outlook.
• Surgical business — Cited alongside Vascular as a driver of second quarter 2026 results; part of the continuing operations that remain after the Strategic Divestitures.
• Acute Care and Interventional Urology (being divested) — Being sold to Intersurgical Ltd for expected proceeds of $530 million; classified as discontinued operations from December 31, 2025 and expected to close in the fourth quarter of 2026.
• OEM business (divested August 2026) — Sold to Montagu and Kohlberg for expected proceeds of $1.5 billion, completed August 3, 2026; the company reported net cash proceeds of $1.5 billion, approximately $1.2 billion after-tax.

Recent performance

Second quarter 2026 revenue from continuing operations was $570.3 million, up 28.9% versus the prior-year period and up 4.7% on a pro forma adjusted constant currency basis. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, while adjusted diluted EPS from continuing operations was $1.76 versus $1.73. Fiscal 2025 revenue was $1.99 billion with a net loss of $905.6 million and diluted EPS of -$20.25, and operating cash flow fell to $96.7 million, down from $301.9 million in 2024. The company completed the OEM sale on August 3, 2026, receiving $1.5 billion in net cash proceeds and repaying the $700 million Term Loan A-2.

Strategy

In February 2025 Teleflex announced a strategic transformation, and on December 9, 2025 it signed definitive agreements for the Strategic Divestitures of Acute Care, Interventional Urology and OEM for combined total cash consideration of $2.0 billion. Management says it will deploy net proceeds to reduce debt, return capital to shareholders and invest in long-term growth. The company announced a $250 million accelerated share repurchase and had already repurchased $250 million of common stock in the second quarter of 2026, under a previously announced $1 billion repurchase program. Stuart A. Randle was appointed Interim President and CEO on January 8, 2026 after the departure of Liam J. Kelly, and the August 2026 release identifies Jason Weidman as President and CEO. Priorities cited include operational rigor, innovation platforms, and integrating the acquired Biotronik Vascular Intervention business.

Risks

• Divestiture execution and timing — The Acute Care and Interventional Urology sale is still subject to regulatory approvals and other closing conditions and is only anticipated to close in the fourth quarter of 2026, and the company's 10-K lists the ability to complete these sales and satisfy conditions as a risk.
• Vascular Intervention integration delay — Management stated the Biotronik Vascular Intervention integration is taking longer than expected due to elongated timelines rather than the product portfolio, and reduced its revenue outlook accordingly.
• Weak 2025 profitability and cash flow — Fiscal 2025 produced a net loss of $905.6 million, diluted EPS of -$20.25 and operating cash flow of $96.7 million, well below the $301.9 million generated in 2024.
• Leadership turnover — The company announced the departure of Chairman, President and CEO Liam J. Kelly in January 2026 and appointed an interim CEO, and has since identified a new President and CEO in its August 2026 release.

Outlook

For 2026 continuing operations, management reduced GAAP revenue growth guidance to 13.40%-14.40% and GAAP EPS to $2.54-$2.84, while increasing adjusted diluted EPS guidance to $6.90-$7.20. Pro forma adjusted constant currency revenue growth guidance was reduced to 3.50%-4.50%. Guidance assumes approximately a 19% adjusted operating margin for 2026 including transition services from the OEM close, and excludes expected benefits from transition services and manufacturing services agreements tied to the Acute Care and Interventional Urology closing, IEEPA tariff refunds, and the announced $250 million accelerated share repurchase and other anticipated buybacks.